证券代码：300404 证券简称：博济医药 博济医药科技股份有限公司 投资者关系活动记录表 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | ■其他（投资者电话交流会） | | | 华创证券、兴业证券、招商证券、太平洋证券、东北证券、光大 | | 参与单位名称 | 证券、开源证券、银河证券、华安证券、华福证券、国泰海通、 | | 及人员姓名 | 西部利得、瑞丰基金、博远基金、富安达基金、瑞天投资、乾璐 | | | 投资、华宝基金、摩根资产、银河基金、长盛基金、招商基金等 | | 时间 | 年 月 日（星期三） 2025 8 27 | | 地点 | 广州 | | 上市公司接待 | 董事长、总经理：王廷春 | | 人员姓名 | 副总经理、董事会秘书：韦芳群 | | | 1、管理层介绍公司经营情况 2、交流互动环节： | | | 问题 1：请问目前公司临床 CRO 业务发展情况如何？订单价 | | | 格水平是否有所回暖？ | | 投资者关系活 动主要内容 | 答：2 ...

科技是强盛之基，创新是进步之魂。当前，中国正以前所未有的决心与力度推进"健康中国"战略的落地 实施。这不仅是满足人民群众对美好生活向往的内在要求，更是驱动我国经济实现新旧动能转换、构筑 国家竞争新优势的战略支点。2024年以来，"创新药"被写入政府工作报告，"积极打造生物制造、创新 药等新增长引擎"的要求被重点强调。政策层面的高调定音，为产业发展注入了强大的确定性。 我国创新医药产业的发展也从"跟随"、"并行"向部分领域的"领跑"迈进，成果斐然。行业数据显示， 2024年全年，我国创新药领域对外授权合作(License-out)总额再创新高，历史性地突破了550亿美元大 关。这一强劲势头在2025年得以延续和加速，仅上半年披露的交易总金额就已接近500亿美元，充分展 现了中国创新药在全球价值链中的地位正迅速提升。 作为始终与国家战略同频共振的私募股权投资平台，坤元资产前瞻性地捕捉到这一历史机遇。相关负责 人表示，在"健康中国"战略稳步推进的宏大叙事下，医药企业的持续创新与深度研发，正成为驱动这一 蓝图实现的核心引擎。当前，中国正处于攻克关键技术壁垒、推动产业结构优化的攻坚期，这为具备高 技术壁垒的"医疗+科技 ...

| | ■特定对象调研□分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访□业绩说明会 | | 类别 | □新闻发布会□路演活动 | | | □现场参观 □其他 | | 参与单位名称及 | 鹤禧投资、鲸域资产、红杉资本、淡水泉、浙商证券资管、中原证券自营、 | | 人员姓名 | 上海环懿私募、浙商证券研究所 | | 时间 | 2025 年 7 月 31 日 15:30-17:30 | | 地点 | 公司会议室 | | 上市公司接待人 | 睿智医药董事会秘书：许剑 | | 员姓名 | 睿智医药证券事务代表、投资者关系管理经理：徐璐瑶、朱子白 | | | 1、胡总上任以来对公司采取了哪些措施或者有哪些影响？ 部门协作顺畅，为业务发展提供了坚实的组织保障。 | | | （1）推进公司管理体系的优化升级：通过科学配置管理团队、明确权责 | | | 分工，建立了更加稳定高效的组织架构。目前公司核心管理层保持稳定，各 | | 投资者关系活动 | （2）强化市场营销与客户拓展体系：首先对 团队进行专业化重组， BD | | | 国内外团队分别设立专职负责人，团队规模从 10 余人扩充至近 30 ...

Group 1 - The CRO concept sector experienced a short-term surge, with Chengda Pharmaceutical (301201) rising over 10% [1] - Other companies such as Xuantai Pharmaceutical, Medisi, Saintno Biological, Sichuan Shuangma (000935), and Dezhan Health (000813) also saw increases [1] - There is a notable flow of "smart money" into the market, indicating a strategic investment trend [1]

Group 1: Financial Performance - In 2024, the company achieved a revenue of 970 million CNY, a year-on-year decrease of 14.77% due to challenges in the innovative drug industry and intense market competition [2][3] - The net profit attributable to shareholders was -226 million CNY, a year-on-year improvement of 75.30% due to reduced asset impairment provisions [3] - In Q1 2025, the company reported a revenue of 261 million CNY, a year-on-year increase of 11.37%, and a net profit of 6.64 million CNY, marking a return to profitability [3] Group 2: Strategic Planning - The company is upgrading its comprehensive service strategy to differentiate itself from competitors, leveraging 20 years of CRO experience to provide integrated solutions from target identification to IND [4] - AI technology is being integrated into drug development processes to enhance operational efficiency and market competitiveness, with ongoing deployment of DeepSeek technology [4] - The company aims to strengthen its domestic and international business development (BD) systems, focusing on major clients domestically and expanding its European team [4] Group 3: Market and Business Development - The company plans to increase its domestic market share, currently below 20%, by enhancing comprehensive service orders and local channel development [5] - The global market, including domestic demand, is showing signs of recovery in 2025, prompting the company to intensify its domestic market development efforts [9] - The company has seen an increase in orders in the ADC and peptide sectors, with strategic expansions into new drug platforms [8] Group 4: Technological Advancements - The company has developed comprehensive capabilities in new molecular and modality areas, including ADC, peptides, and PROTAC, with over 2,000 linker-payload designs completed [7][11] - The company has established a complete one-stop service platform for ADC/XDC drug development, covering all stages from target validation to clinical application [10] - Continuous investment in new modalities and technologies is planned to maintain competitive advantages in drug development [11] Group 5: Collaboration and Partnerships - The company has maintained a long-term partnership with Eli Lilly, successfully passing their site audit, and continues to collaborate with various subsidiaries [11] - Strategic collaborations with universities enhance the company's technical reserves and support future order acquisition [12]

Group 1: Company Performance and Orders - In 2024, the company expects to achieve approximately 1.515 billion CNY in new orders, representing a year-on-year growth of about 30.07% [2] - The company anticipates that the growth rate for new orders in the traditional Chinese medicine CRO sector will be around 20%, accounting for approximately 30% of total new orders in 2024 [3] - As of the end of 2024, the company has unrecognized revenue from contracts amounting to approximately 2.759 billion CNY, with an expected 682 million CNY to be recognized as revenue in 2025 [4] Group 2: Market Conditions and Competition - The CRO market remains highly competitive, with some smaller CRO companies facing operational difficulties, layoffs, or even liquidation, leading to an expected increase in industry concentration [3] - The company maintains a strong competitive advantage due to its established presence and resources in the CRO market [3] - The nuclear medicine CRO market is emerging, with few companies having relevant project experience, which positions the company favorably for future projects [8] Group 3: Profitability and Margins - The company expects the gross margin for clinical business to slightly decline due to ongoing market competition, while the gross margin for preclinical business remains stable [4] - Despite the anticipated decline in gross margin, the company is focused on reducing costs and believes that net profit margins will not decrease [4] Group 4: Future Plans and Innovations - The company plans to continue focusing on clinical services while also developing preclinical research and drug evaluation services, as well as contract development and manufacturing organization (CDMO) services [6] - There are ongoing discussions for the transfer of self-developed projects, with expectations to achieve significant milestones in 2025 [5] - The company is actively exploring AI applications in clinical trial design and data analysis, with plans to expand its use in clinical monitoring and preclinical compound screening [9]

希格玛会计师事务所(特殊普通合伙) Xigema Cpas(Special General Partnership) 关于新疆百花村医药集团股份有限公司 非公开发行股票申请之二次反馈意见回复 中国证券监督管理委员会: 贵会 2022 年 6 月 24 日下发的《中国证监会行政许可项目审查二次反馈意 见通知书》(220241 号)(以下简称"《二次反馈意见》")收悉。根据贵会《二次 反馈意见》提出的要求,我们在审慎核查的基础上,就《二次反馈意见》中的有 关问题回复说明如下: 反馈意见 1:2018年至2021年,申请人实现的净利润分别为:亏损67,529.15 万元,盈利 3,438.47 万元、亏损 31,976.55 万元及盈利 5,987. 43 万元;过往 4 年申请人收入存在巨幅波动,2020年营业收入为8,453.04万元,远小于当期结 转的营业成本 22,143.09万元。截止 2021年12月31日,发行申请人存货余额 19,404.78 万元,主要为在研项目《占比 99.67%);合同资产余额 14,554. 33 万 元,全部为研发项目。 请申请人:(1)说明过往 4年经营业绩大幅波动的原因 ...